The James Buchanan Brady Urological Institute
  Biomarker Research Laboratory          
Image Analysis Technology
Proteomics Technology
Biorepository & Informatics
Contact Us


The biorepository includes a serum-urine bank of over 5,000 specimens that is supported by an EDRN-CEVC grant and Dr. Alan W. Partin is the P.I. and Dr. Veltri is one of the co-investigators for the project.  Below are the Research Aims for this NCI-EDRN project.
Aim 1: Specimen Collection and Utilization -  Collection and archiving of matched serum and urine specimens for biomarker research.  Continue collection of serum and urine specimens (app. 300/year) from men who are in the early detection, diagnosis, treatment and monitoring stages for prostate cancer.  All specimens are collected under IRB approved, informed consent protected, mandatory EDRN CDE, HIPAA compliant circumstances.  All specimens are available for collaborative research through proper EDRN/NCI- Investigator approval processes for EDRN purposes.  Sample collection and processing protocols are clearly illustrated below.  Ms. Leslie Mangold manages this process with a team shown here.

Aim 2:  Participation in prospective EDRN coordinated Validation Studies of Biomarkers for Prostate Cancer.

Aim 3:  Continue Pre-Validation evaluation of several promising prostate cancer tumor markers.

Aim4:  Due to budget adjustments at the time of the award, this specific aim, as it corresponds to our original proposal, was removed at the recommendation of NCI program staff.

Aim 5: Exploratory analyses of novel tumor marker technologies and multi-variable model development.  


Currently, the Partin Prostate Cancer Database consists of >14,000 cases that include post-operative pathology and follow-up for outcomes.  The latest contemporary database (n=5730) analysis was the updated 2007 Partin Tables (Makarov DV et al. Urology 2007; 69(6):1095-101).  The Buchanan Brady Urological Institute at where the computer programs available based upon the Partin Databases {Partin and the Han Tables}.

Also, the Partin Tables can be expressed using a "Predictiveness Curve" statistical approach (Huang Y et al. Biometrics 63; 1181-1188) where biomarkers can used as continuous variables to construct predictive model. Drs. Ying Huang and Ziding Feng at the Fred Hutchinson Cancer Research Center in Seattle, WA are currently working on this approach to further enhance predictive accuracy of Partin Table.  In the future, we anticipate adding several more input variables (e.g. quantitative biopsy pathology) to increase predictive accuracy of Partin Table for post-operative pathology outcomes (i.e. OC, EPE, SV+, or LN+).

Finally, there are numerous urologists, post-doctoral research fellows, scientists and technical staff that have contributed to the development of the technical resources and generation of the results and concepts described above for the Fisher Laboratory and many of these contributors are listed in the urology publications produced. The following personnel have rotated through the Fisher Biomarker Laboratory since 2002; Dr. Mathew Gretzer (urologist) trained at JHUSOM, Dr. Masood A. Khan (urologist from Great Britain) and research fellow, and Dr. Danil V. Makarov (urologist) trained at JHUSOM.

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.| Disclaimer
Email: | 600 North Wolfe Street, Baltimore, Maryland 21287